CG Oncology highlighted Cohort C of the Phase 3 BOND-003 trial of cretostimogene in high-risk, BCG-unresponsive bladder cancer patients with carcinoma in situ. Mayo Clinic’s Mark Tyson emphasized the unmet need.
published
CG Oncology highlighted Cohort C of the Phase 3 BOND-003 trial of cretostimogene in high-risk, BCG-unresponsive bladder cancer patients with carcinoma in situ. Mayo Clinic’s Mark Tyson emphasized the unmet need.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.